Submit a new drug application for Yselty in the U.S
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- September 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“prepare to file a new drug application (NDA) in the U.S. in the first half of 2021 for Yselty”
What we found
Evidence strength A What the grades mean
The company committed to submitting the NDA in the first half of 2021, but filings confirm the submission occurred in September 2021.
-
A ObsEva S.A. 20-F filed 2022-03-10
“In September 2021, we submitted a NDA to the FDA, for linzagolix for the treatment of uterine fibroids.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- New drug application for Yselty
- Where
- U.S.
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ObsEva S.A.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C685316-020996 · Corrections policy